Fisher & Paykel Healthcare Introduces New CPAP Range

Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it has introduced into Australia and New Zealand its new ICON continuous positive airway pressure (CPAP) devices for the treatment of obstructive sleep apnea (OSA).

The ICON range integrates Fisher & Paykel Healthcare’s leading technologies into stylish, compact and intelligent devices to deliver a better night’s sleep for OSA patients. The F&P ICON also includes a digital clock, alarm and music playing capabilities to enhance patient adaptation to CPAP therapy.

“The ICON combines both exceptional style and technology to fit unobtrusively into the home setting. It has a very small footprint and incorporates our innovative technologies including, SmartStick, ThermoSmart and SensAwake”, commented Michael Daniell, Fisher & Paykel Healthcare’s Chief Executive Officer.

The product range spans three models; Auto, Premo and Novo. The Auto detects interruptions to normal breathing and provides the appropriate positive airway pressure to meet the breath-by- breath needs of the patient with full efficacy and compliance reporting. The Premo model provides fixed pressure therapy with efficacy and compliance reporting, while the Novo provides basic compliance reporting.

The ICON range also includes Fisher & Paykel’s InfoSmart technologies, which will provide a full range of communication and compliance reporting options.

“We are delighted with the positive response to ICON from CPAP users, clinicians and home care providers and we are looking forward to progressively introducing the range into our international markets this year”, concluded Mr Daniell.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company visit

Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119. For high resolution images please contact